ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs placebo
Adverse effects ‐ any adverse effect · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyRR 1.5 [0.92, 2.45]1 study · 100 participantsLow